Transdermal testosterone pretreatment in poor responders with androgen receptor polymorphism undergoing ICSI: A Randomized Clinical Investigation.

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510596-37-01

Enrollment

100

Registered

2025-10-06

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

low ovarian reserve according to Bologna criteria and carriers of androgen receptor polymorphism

Brief summary

number of oocyte cumulus complexes obtained

Detailed description

Number of metaphase II stage oocytes obtained., Duration of stimulation (days), Dose of medication used, Fertilization rate, Blastocyst formation rate, Cancellation rate, Viable intrauterine gestation (confirmed by ultrasound)

Interventions

DRUGDecapeptyl diario 0

DRUG1 mg polvo y disolvente para solución inyectable

DRUGAstarté 0

DRUG25 mg/0

DRUG5 ml solución inyectable en jeringa precargada EFG

DRUGTestosterone Gel 1%

DRUGBemfola 300 IU/0.50 mL solution for injection in pre-filled pen

DRUGBomba de gel transparente

DRUGdonde la sustancia activa (testosterona) fue sustituida por agua purificada.

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
number of oocyte cumulus complexes obtained	—

Secondary

Measure	Time frame
Number of metaphase II stage oocytes obtained., Duration of stimulation (days), Dose of medication used, Fertilization rate, Blastocyst formation rate, Cancellation rate, Viable intrauterine gestation (confirmed by ultrasound)	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026